How to Get Jardiance in Michigan: Prescriptions, Telehealth, and Pharmacy Access

Jardiance is the brand name for empagliflozin, an SGLT2 (sodium-glucose co-transporter 2) inhibitor tablet taken once daily, marketed by Boehringer Ingelheim in partnership with Eli Lilly. It is not the same drug as GLP-1 injectables like semaglutide or tirzepatide, and it works by a different mechanism: blocking glucose reabsorption in the kidney so excess sugar is excreted in urine. The FDA has approved empagliflozin for three separate indications: type 2 diabetes, heart failure (both reduced and preserved ejection fraction), and chronic kidney disease (CKD) with or without diabetes [1].

Michigan does not require an in-person visit before a Jardiance prescription can be issued. Under Michigan's telehealth statute, a licensed prescriber can establish a valid patient-prescriber relationship through a real-time audio-video visit, which is sufficient to generate the prescription [2]. What Michigan law does not remove is the need for baseline kidney function testing, a legitimate clinical indication, and, for most insured patients, a prior authorization approval before the pharmacy claim goes through. The rest of this page separates what is fixed (FDA labeling, state telehealth law) from what changes by plan, insurer, and year (prior authorization criteria, cash price, savings card terms) so you know which facts to trust as stable and which ones to re-check before you act.

The core answer for most readers: a Michigan resident can obtain empagliflozin through an in-person or Michigan-licensed telehealth prescriber without a prior in-person visit, using a same-day electronic prescription; the clinical prerequisite that does not vary by insurer is a recent eGFR, because the FDA label restricts initiation below an eGFR of 20 mL/min/1.73 m² and limits the 25 mg dose for glycemic control below 45 mL/min/1.73 m² [1]. What does vary, and must be checked at the time of the visit, is whether a specific commercial or Medicaid plan requires prior authorization and what its current cost-sharing looks like.

What Jardiance is approved to treat

The FDA-approved indications are glycemic control in adults with type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, reduction of heart failure hospitalization and cardiovascular death in adults with heart failure (across ejection fraction categories), and slowing of CKD progression in adults with and without diabetes [1]. The current FDA label, available through the agency's drug approval database, is the authoritative source for dosing, contraindications, and the eGFR cutoffs described below [1].

Empagliflozin's use as a cardiorenal protective agent, not just a glucose-lowering drug, is supported by a series of large cardiovascular and kidney outcome trials, including EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY. These trials are widely cited in cardiology and nephrology literature and are the basis for the drug's cardiovascular and renal indications. This draft does not carry specific effect-size figures (relative risk reductions, hazard ratios) forward from the prior version of this page, because the underlying citation identifiers could not be independently verified during this review. A clinician or editor confirming exact trial results should pull the original New England Journal of Medicine publications directly rather than relying on a secondary summary.

The American Diabetes Association's Standards of Care recommends SGLT2 inhibitors, as a class, for people with type 2 diabetes who also have established cardiovascular disease, heart failure, or CKD, independent of baseline HbA1c [3]. That guideline recommendation, not a specific trial percentage, is the most defensible clinical anchor for "why a Michigan clinician might prescribe this even when blood sugar is already at goal."

Dosing and the one lab result that is not optional

Empagliflozin comes only as commercial 10 mg and 25 mg tablets, taken once daily with or without food. The 10 mg dose is generally sufficient for cardiovascular and renal indications; the 25 mg dose is reserved for patients who need additional glycemic lowering and whose kidney function supports it [1].

A baseline eGFR is the one lab result every legitimate Michigan prescriber, in person or via telehealth, should request before writing the prescription, because the label restricts use at low eGFR: not recommended for glycemic control below 30 mL/min/1.73 m², and not to be initiated for any indication below 20 mL/min/1.73 m² [1]. Beyond eGFR, a comprehensive metabolic panel (covering creatinine, glucose, and electrolytes) and, for the diabetes indication, a recent HbA1c are standard. A urine albumin-to-creatinine ratio is often collected when CKD is the indication, both clinically and to support insurer documentation. Potassium is worth checking in patients already on a diuretic or an ACE inhibitor/ARB, since empagliflozin has a mild diuretic effect.

This is general prescribing information, not individualized dosing guidance. The starting dose, titration, and monitoring interval for any individual patient should be set by the prescribing clinician based on that patient's kidney function, other medications, and clinical history.

How the prescription actually gets written in Michigan

Michigan's Public Health Code allows a prescriber to establish a valid patient relationship through synchronous, real-time audio-video telehealth, which is sufficient for issuing a prescription, including for empagliflozin [2]. Asynchronous, questionnaire-only prescribing without any real-time visit does not satisfy this standard.

A typical path looks like this:

1. A visit occurs, in person with a primary care physician, endocrinologist, or cardiologist, or by synchronous video with a Michigan-licensed telehealth prescriber.
2. The prescriber reviews diagnosis, current medications, and prior SGLT2 inhibitor use.
3. Baseline labs (at minimum a metabolic panel with eGFR, plus HbA1c if the indication is glycemic control) are reviewed or ordered.
4. The prescription is transmitted electronically to a Michigan pharmacy of the patient's choosing, retail, independent, mail-order, or a licensed compounding pharmacy.

Michigan participates in the Interstate Medical Licensure Compact, which allows some out-of-state telehealth physicians to hold a Michigan license and prescribe directly to Michigan pharmacies. Any prescriber, MD, DO, nurse practitioner, or physician assistant, with active Michigan prescriptive authority can write for empagliflozin; it is not a controlled substance, so no DEA registration is required for that reason alone [2]. Scope-of-practice details for NPs and PAs (independent versus supervised prescribing) have changed in Michigan in recent years; the current rule in effect should be confirmed against the Michigan Board of Nursing or Board of Medicine rather than assumed from an older description.

Prior authorization and cost: what changes by plan and year

This is the part of the page most likely to go stale, and where a Michigan reader should verify details directly with their own plan rather than rely on generic figures.

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) has historically covered empagliflozin across its FDA-approved indications with prior authorization required. The general shape of PA criteria for the diabetes indication, an HbA1c above a threshold and documented metformin use or a contraindication, is a common Medicaid PA pattern for this drug class, but the exact current criteria, form, and turnaround time should be confirmed with the Michigan Medicaid pharmacy program or the specific managed care plan at the time of the request, since these details change without a public change log.

Commercial insurers operating in Michigan typically tier brand-name Jardiance as a non-preferred or specialty-tier drug, which usually means a higher copay or coinsurance than a generic. Cash price and manufacturer savings card terms change over time; Boehringer Ingelheim publishes current savings program eligibility and copay caps on its own site, and that source, not a fixed dollar figure repeated from an older article, is the one to check before a patient commits to a cash-pay plan [4]. Medicare Part D coverage varies by plan formulary, and the federal $2,000 annual out-of-pocket cap under the Inflation Reduction Act applies to Part D enrollees as of the 2025 benefit year; whether that changes Jardiance's practical cost for a given Medicare beneficiary depends on their specific plan's placement of the drug.

If a prior authorization is denied, Michigan insurance regulation generally requires insurers to state the specific criteria that were not met and to offer an expedited appeal pathway for urgent situations; the exact timelines for standard versus expedited review should be confirmed with the Michigan Department of Insurance and Financial Services or the plan's own appeal documentation, since these are regulatory details subject to periodic revision.

Compounded empagliflozin: what it is and is not

Empagliflozin is commercially available only as 10 mg and 25 mg tablets. A 503A compounding pharmacy licensed in Michigan may prepare a patient-specific formulation, for example an alternative strength or a liquid form for a patient who cannot swallow tablets, provided the compounded product is not an unauthorized copy of the commercial tablet and meets a documented patient-specific need [5]. Michigan's Bureau of Professional Licensing oversees state pharmacy compliance, and compounding must also meet USP Chapter 795 standards.

A compounded product has not gone through the FDA approval process and does not carry the bioequivalence data behind the commercial tablet. Most Michigan clinicians default to the commercial product unless there is a specific, documented reason not to. A pharmacist cannot substitute a compounded version for a commercial Jardiance prescription without the prescriber's explicit authorization.

Monitoring after starting Jardiance

Once a patient starts empagliflozin, reasonable monitoring generally includes a repeat eGFR and creatinine within the first one to two months, then periodically thereafter with frequency depending on baseline kidney function [1][3]. HbA1c is checked periodically for patients using the drug for glycemic control. Genital mycotic infections are a known class-associated side effect and worth raising at follow-up visits. Patients are commonly advised to hold the drug for several days before elective surgery or a prolonged fast, because SGLT2 inhibitors carry a small risk of euglycemic diabetic ketoacidosis, ketoacidosis without markedly elevated glucose, a risk reflected in current diabetes care guidelines [3].

The FDA's labeling for the SGLT2 inhibitor class includes a lower-limb amputation warning that originated from trial data on a different drug in the class (canagliflozin); readers and clinicians comparing amputation risk across specific SGLT2 inhibitors should consult the current FDA label for empagliflozin directly rather than assume the same magnitude of signal applies [1].

What is established, what is plausible, and what needs verification

Established by FDA label and Michigan statute: empagliflozin's three approved indications, its dosing range, the eGFR-based restrictions on initiation and titration, and Michigan's allowance of prescription issuance after a synchronous telehealth visit [1][2].

Plausible and guideline-supported but not something this page can quantify precisely: the magnitude of cardiovascular and renal risk reduction reported in the major outcome trials. The trials exist and are well known in the literature; this draft avoids repeating specific percentages because the citation trail supporting those exact figures could not be verified for this rewrite.

Not established on this page, and dependent on facts outside stable federal law: specific Michigan Medicaid PA turnaround times, specific commercial insurer tier placements, current cash price, and current manufacturer savings card terms. These are the facts most likely to have changed since this page was last checked and should be reconfirmed directly.

Verification checklist: what's stable versus what expires

Review this information before making decisions based on this article. The first category includes requirements established by federal law or state regulations that remain stable over time. The second category encompasses policies determined by your insurance company, pharmacy, or Boehringer Ingelheim and Eli Lilly (empagliflozin's manufacturers) that may be updated at any time.

Stable, low-need-to-recheck facts (federal label and state law):

• Empagliflozin's three FDA-approved indications (type 2 diabetes, heart failure, CKD), confirm against the current FDA label if a new indication is claimed [1].
• The eGFR cutoffs restricting initiation (below 20) and the 25 mg dose for glycemic control (below 45) [1].
• Michigan's statutory allowance of prescription issuance following a synchronous audio-video telehealth visit, without a prior in-person visit requirement [2].
• Empagliflozin's non-controlled status (no DEA registration required for that reason).
• The existence of a 503A compounding pathway for patient-specific formulations, governed by FDA and Michigan pharmacy board rules [5].

Date-sensitive facts you must re-verify at the time of use:

• Whether your specific Medicaid managed care plan or commercial insurer requires prior authorization this year, and its exact documentation requirements.
• Standard and expedited prior authorization turnaround times for your specific plan.
• Current cash price at your chosen pharmacy and current manufacturer savings card eligibility and copay cap [4].
• Whether your Medicare Part D plan places Jardiance on a formulary tier that benefits from the annual out-of-pocket cap.
• Current scope-of-practice rules for NP and PA prescribing authority in Michigan, since these are periodically updated by the state legislature and licensing boards.
• Which specific pharmacy chains or 503A compounders in your area currently stock or compound the product.

If a fact you need falls in the second group, treat anything you read here, or in any other secondary source, as a starting point for a call to your insurer, pharmacy, or the Michigan Medicaid pharmacy program, not as a final answer.

When to seek care outside this process

This page describes a routine outpatient medication-access pathway. It does not apply to a patient in diabetic ketoacidosis, with signs of a severe genital or urinary infection, with acute kidney injury, or with any acute decompensation of heart failure. Those situations require urgent or emergency evaluation rather than a scheduled telehealth visit for a prescription refill.